This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
General Information
Rat: Wistar
The full-length human mutant (T240R) Parkin gene is expressed unilaterally in the SN using Adeno-Associated virus 2/8 (AAV2/8).
Endogenous Parkin: Yes
Corresponding human genotype: The T240R mutation is one of the first point mutations identified in the Parkin gene.
Targeted gene: Parkin
References: Van Rompuy 2014
Viral injection
Injection coordinates: Right SN -. one deposition site: AP −3.1 mm, ML −1.2 mm, DV −4.0 mm.
Volume of injection and viral titer: two microliters of AAV2/8 vector are injected at a concentration of 2 × 1011 GC/ml
Transgene expression
4 and 12 days then 1, 2, 4 and 8 months post-injection: The transgene is expressed in neurons of the SN and ventral tegmental are (VTA); very little expression is detected in astrocytes and microglia cells. The volume of the transduced area is maximal after 12 days and gradually decreases thereafter.
Neurodegeneration
1, 2, 4 and 8 months post-injection: Loss of TH- positive neurons in the SN is visible 2 months post-injection and increases over time. Similar degeneration is observed in VMAT2 expression (immunostaining). The loss of TH positive projections is maximal at 4 months; a partial recovery can be observed 8 months post-injection.
Dopamine Homeostasis
Not reported
Inclusions
Not reported
Motor Behaviours
4 days then 1, 2, 4 and 8 months post-injection: No significant changes is observed in the cylinder test.
Response to dopaminergic treatment
Not reported
Non-motor Behaviours
Not reported
Electrophysiology
Not reported
Neuroinflammation
4 days and 1 month: An increased inflammation is observed mostly along the needle track (CD68 staining) in the rats expressing the human T240R gene after one month.